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MINI-SYMPOSIUM
Sirolimus eluting stent implantation for patients with
multivessel disease: rationale for the arterial
revascularisation therapies study part II (ARTS II)
P W Serruys, P A Lemos, B A van Hout, on behalf of the ARTS II Steering Committee and
Investigators
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n-stent restenosis and the need of repeat revascularisation
remain the major limitations of coronary angioplasty for
patients with multivessel disease.1 2 Utilisation of drug
eluting stents in this context is expected to have a major
impact on the effectiveness of percutaneous treatment.
Sirolimus eluting stent implantation has recently been shown
to significantly reduce coronary restenosis, with zero angio-
graphic restenosis3 4 and persistent long term neointimal
inhibition.4 Moreover, sirolimus eluting stents were proven to
be as safe as bare metal stents at 30 days in a group of
patients with acute coronary syndromes and a high frequency
of multivessel disease.5 However, currently the effect of this
device on long term outcomes of patients with multivessel
disease is largely unknown.
EARLY CLINICAL EXPERIENCE: THE RESEARCH
STUDY
The sirolimus eluting stent received Conformite´ Europe´enne
mark approval in April 2002, since when it has been available
for routine use in Europe. From 16 April 2002, it has been the
policy of our institution to utilise sirolimus eluting stents as
the device of choice for all percutaneous coronary interven-
tions, as part of the RESEARCH (rapamycin-eluting stent
evaluated at Rotterdam Cardiology Hospital) study, which is
a single centre registry conducted with the main purpose of
evaluating the efficacy of sirolimus eluting stent implanta-
tion in the ‘‘real world’’.5
In a preliminary analysis, the first 150 patients with
multivessel disease included in the RESEARCH study were
compared to a control group formed by 150 consecutive
patients treated with bare stents in the period immediately
before. Both groups were similar at baseline regarding the
frequency of previous bypass surgery (19% v 18%, respec-
tively; p = 1.0), three vessel disease (32% v 35%, respec-
tively; p = 0.6), and diabetes (27% v 22%, respectively;
p = 0.4). At six months follow up, the cumulative incidence
of major adverse cardiac events (death, myocardial infarc-
tion, or repeat revascularisation) was significantly lower
among those treated with sirolimus eluting stents (10.0% v
20.7% in controls; p = 0.01), mainly due to a pronounced
reduction in the need for further revascularisation (3.3% v
12.7%; p = 0.003) (fig 1). Although promising, however,
these preliminary findings must be interpreted with caution
until further confirmation with larger number of patients and
more prolonged follow up is available.
SIROLIMUS ELUTING STENT OR SURGERY FOR
PATIENTS WITH MULTIVESSEL DISEASE? THE ARTS II
STUDY
The premise and the philosophy of ARTS II
Against the background of the impressive results of sirolimus
eluting stent implantation in patients with single vessel
disease and the promising initial findings of the RESEARCH
study, the next ideal step should be a new randomised trial
comparing treatment with multivessel stenting with the
sirolimus eluting stent with the most advanced and up to
date surgical treatment. However, before designing this new
randomised trial it seems wise to improve the capabilities in
treating complex multivessel disease (for example, main
stem, total chronic occlusion, bifurcation, long lesion, small
vessel). On the other hand, time is also needed in order to
implement and vulgarise new surgical techniques that have
been recently introduced and fully mastered in only certain
centres of excellence. Therefore the ARTS II (arterial
revascularisation therapies study part II) trial must be
perceived as an intermediate phase towards the next full
fledge second randomised ARTS trial.6
ARTS II is as a multicentre, non-randomised, open label,
stratified trial designed to evaluate sirolimus eluting stent
implantation in patients with multivessel disease using the
surgical group of ARTS I as an historical control. To be
comparable to the results of the ARTS I study, patients
included in the ARTS II trial must present similar baseline
Abbreviations: ARTS, arterial revascularisation therapies study; CABG,
coronary artery bypass graft surgery; CCS, Canadian Cardiovascular
Society; MACCE, major cardiac and cerebrovascular events;
RESEARCH, rapamycin-eluting stent evaluated at Rotterdam Cardiology
Hospital
Figure 1 Cumulative incidence of major adverse cardiac events (death,
myocardial infarction, or repeat revascularisation) at six months for
patients with multivessel disease treated with sirolimus eluting stents
(SES) or bare metal stents (control). The incidence of repeat
revascularisation during follow up is shown below.
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characteristics. In order to ensure recruitment of a population
very similar to the one of ARTS I, methodological techniques
as ‘‘pseudo’’ randomisation or stratification will be applied.
Objectives
The main goal of the ARTS II trial is to assess a non-
inferiority of sirolimus eluting stent implantation for patients
with multivessel disease with respect to the previous result of
the surgical arm of the ARTS I trial.
The primary objective of ARTS II is to compare the
effectiveness of coronary stent implantation using the
sirolimus eluting Cypher (Cordis Johnson & Johnson,
Warren, New Jersey, USA) balloon expandable stent with
that of surgery as observed in ARTS I. Effectiveness is
measured in terms of major cardiac and cerebrovascular
events (MACCE)-free survival at one year:
N death
N cerebrovascular event
N non-fatal myocardial infarction
N repeat revascularisation (either percutaneous or surgical).
The secondary objectives of this study are to compare the
two groups with respect to:
N MACCE at 30 days, six months, and three and five years
N total cost at 30 days and cost, cost effectiveness, and
quality of life at six months, and one, three, and five years
N combined end point death, myocardial infarction and
stroke, and the itemised outcomes death, myocardial
infarction, revascularisation procedure, stroke
N resource use at 30 days and one year.
End point definitions
Death
In case of death its exact cause will be recorded whenever
possible on the basis of a necropsy. All deaths are considered
cardiac unless there is documentation to the contrary.
Secondary analysis will look separately at cardiac and non-
cardiac death.
Cerebrovascular event
Cerebrovascular events will be divided into three main
categories: stroke, transient ischaemic attacks, and reversible
ischaemic neurologic deficits.
Myocardial infarction
All myocardial infarctions will be counted as events, whether
they occurred spontaneously or in association with angio-
plasty or coronary artery bypass graft surgery procedures. A
definite diagnosis of myocardial infarction is made:
N first seven days post-intervention when both following
criteria are positive:
– new abnormal Q waves not present at baseline
(Minnesota code)
– creatinine kinase 26 normal (routine collection at six
and 12 hours post-procedure and at discharge.
N after seven days from any intervention when at least two
of the following occur:
– chest discomfort of at least 20 minutes duration
– new abnormal Q waves not present before allocation
(Minnesota code)
– creatinine kinase . 26upper limit.
Revascularisation procedure
Every subsequent revascularisation procedure is recorded,
either percutaneous or surgical.
Cost effectiveness
Direct medical cost—Resource use concerning the initial
procedure, hospital admissions, and major diagnostic or
therapeutic procedures after the initial procedure.
Quality of life—The patient’s quality of life will be assessed
by the EuroQol and the SF-36 questionnaire (at randomisa-
tion, 30 days, six months, one year, three years, and five
years). Furthermore, at the same point in time, the patient’s
anginal status will be assessed by the Canadian Cardio-
vascular Society (CCS) classification and the Braunwald
classification. Before the procedure, and at all planned follow
up visits, patients will be asked to fill out a questionnaire
concerning their work status.
Study population and stratification (‘‘pseudo
randomisation’’)
A total of 600 eligible patients will be selected from the daily
practices of 45–50 centres across Europe with a minimum
enrolment of 12 eligible subjects per centre. Inclusion and
exclusion criteria are presented in table 1. Patients are
stratified by clinical site in order to ensure inclusion of one
third of three vessel disease versus two thirds of two vessel
disease, as based on the patient population enrolled in ARTS
I. An ongoing check on the success of matching with the
historical control will be performed. If it appears that the
population has less than 2.7 lesions, the recruitment scheme
of ‘‘3-2-2’’ will be changed to ‘‘3-3-2’’.
Stent procedure and antiplatelet regimen
The sirolimus eluting Cypher balloon expandable stent is pre-
mounted and crimped on the Raptor stent delivery system
5SDS. Direct stenting or pre-dilatation is left to the
investigator’s discretion. In case of inadequate positioning
(uncovered lesion), dissection or unmasking of a narrowing
in the inflow or outflow area of the implanted stent, a second
or third stent may be placed in series. Intravascular
ultrasound or any other monitoring devices are allowed. A
multi-staged procedure is allowed and should be declared
either before the initial procedure or at the time the patient is
leaving the interventional suite. Patients who do not have all
diseased vessels dilated, but all targeted vessels are success-
fully dilated, will be classified as ‘‘incompletely revascu-
larised by intent’’. Those who do not have all targeted vessels
successfully dilated will be classified as ‘‘incompletely
revascularised, but not by intent’’.
Clopidogrel (preferably) or ticlopidine for eight weeks
(75 mg/day or 26 250 mg daily, respectively) and lifelong
aspirin are commended. Clopidogrel (preferably) or ticlopi-
dine should be used for at least six months for patients with
diabetes or chronic total occlusion. Administration of
glycoprotein IIb/IIIa inhibitors will only be considered in
case of high instability, which cannot be controlled by any
other means.
Statistical analysis
Assumptions for comparative analysis
Due to the expected pronounced decrease in the need for
repeat revascularisations, the incidence of MACCE after
sirolimus eluting stent implantation is probably best esti-
mated as the proportion of patients in ARTS with death/
cerebrovascular accident/myocardial infarction (that is, 9.1%
after pooling the data from both ARTS treatment arms).
ARTS II will not consider surgery as a separate arm and
therefore the uncertainty margins need to be defined in
advance. The ARTS I trial suggests a point estimate of 87.8%
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with a 95% confidence interval of 83.4% to 92.3%. In order to
reflect the additional uncertainties due to eventual (minimal)
changes of surgery over the time since the recruitment of the
ARTS trial and/or mismatches between the two trials with
respect to patient characteristics, the variance will be inflated
by 25%.
Sample size
For the sample size calculations several approaches were
taken into consideration, both concerning clinical and cost
and cost effectiveness outcomes, using Bayesian and fre-
quentist methodology. It was decided to take the comparative
statistical methodology, using a mixture of Bayesian and
frequentist methodology.
A sample size of 600 patients is chosen to guarantee a
power of at least 90%. The sample size justification is based
on the comparison of the ARTS I stented patients and the
ARTS I surgery patients of the primary end point (one year
MACCE). The null hypothesis is that the one year MACCE-
free survival rate is at least as good as surgery minus 3.5%,
being 84.3%. In the stented group an expected MACCE-free
survival rate of 90.9% is used. This will be tested using a
Bayesian approach.7 A one sided t test will be performed with
a type I error rate of 0.05. Furthermore, an indication of the
precision of the outcome of the ARTS II trial as a one arm
registry is given as the width of the 95% two sided confidence
intervals, being 4.8% (the 95% confidence interval around
90.9% is 88.3% to 93.1%).
Descriptive statistical methodology
Safety data of the 30 days, six months, one, three, and five
years will be analysed; however, the formal Bayesian analysis
of the primary objective will only be performed at one year. A
final analysis on the safety data will be performed at five
years.
Effects
Count variables will be given as group rates and their
matching 95% confidence interval. Time-to-event variable
will be presented as Kaplan-Meier curves. Continuous
variables will be given as group means, and their matching
95% confidence intervals, and as the median, and the 10th
and 90th centiles.
Costs and cost effectiveness
Distinction is made between the direct medical costs and the
total costs including the indirect medical costs. Emphasis is
placed on the direct medical costs that are calculated as the
product of the vector of resource used with a vector of unit
costs. The indirect non-medical costs are addressed in terms
of days of absence from work. In terms of effects, distinction
is made between event-free survival and quality adjusted life
years gained (estimated using two indices). As a result, six
estimates result of the cost effectiveness ratio and the
uncertainty surrounding these six estimates will be addressed
by the methodology as outlined by van Hout and colleagues.8
Comparative statist ical methodology
The primary analysis will be based on the intention-to-treat
principle.
For the primary end point (MACCE at one year),
comparing the ARTS II results with the historical controls
of the ARTS trial, a Bayesian analysis will be used. Random
and fixed effects will be pre-defined.
Analysis with respect to the cost effectiveness end points
will be performed for the predefined subanalysis: two versus
three vessel disease, age, and insulin dependent diabetes.
CONCLUSION
The ARTS II study, with enrolment started in early 2003 and
rapidly proceeding, should provide evidence of the effects of
Table 1 Principal inclusion and exclusion criteria of ARTS II
Inclusion criteria
l Patients with stable (CCS 1, 2, 3, or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris
considered for coronary revascularisation (angioplasty or CABG). Patients with atypical chest pain or
asymptomatic are eligible provided they have documented myocardial ischaemia
l At least 2 lesions de novo (located in different native vessels and in different territories) potentially amenable to
stent implantation
l Multivessel disease with at least one significant stenosis (.50% by visual estimation) in the left anterior
descending artery and with treatment of the lesion in another major epicardial coronary artery
l Left ventricular ejection fraction should be at least 30%
l One total occluded major epicardial vessel or side branch can be included and targeted as long as one other
major vessel has a significant stenosis amenable for stenting, provided the age of occlusion is less than one
month. Patients with total occluded vessels of unknown duration or existing longer than one month and a
reference over 1.50 mm should not be included
l Stenosis amenable to stenting by a stent ranging from 2.5–3.5 mm
l Written informed consent
Exclusion criteria
l Under the age of 18 years, older than 80 years
l Previous CABG, PCI, or CVA
l Pregnant women or women with potential childbearing
l Clinical follow up over a period of five years judged to be difficult or unlikely or concomitant non-cardiac
disease likely to limit long term prognosis
l Overt congestive heart failure
l Myocardial infarction ,7 days
l Left main stenosis of >50%
l Intention to treat more than one totally occluded major epicardial vessel
l A side branch larger than 1.5 mm covered by the stent constitutes an exclusion criterion, unless the operator is
willing and technically able to maintain access to this side branch with either further balloon angioplasty (1.5–
2.5 mm) or stent placement (.2.5 mm)
l Acute or chronic renal impairment (serum creatinine .150 mmol/l or creatinine clearance ,50 ml/min)
l Known allergies to the following: aspirin, clopidogrel, ticlopidine, heparin, stainless steel, contrast agent (that
cannot be managed medically), or sirolimus
CABG, coronary artery bypass graft surgery; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular
accident; PCI, percutaneous coronary intervention;
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percutaneous coronary intervention with sirolimus eluting
stents for patients with multivessel disease, as compared to a
historical control group composed of the surgical arm of the
ARTS I trial. The ARTS II trial should thereby help to clarify
the impact of the new strategy in this context. Nevertheless,
it is clear that during this decade further assessment in
respect of the values of these two modalities of revascular-
isation should be assessed in a major and maybe final
randomised trial.
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Aortic dissection with compression of the ostium of the right coronary artery: visualisation by 16 row
multislice CT
A
73 year old man with known coronary artery disease
and acute coronary syndrome was referred for coronary
angiography. ST element elevation occurred during
contrast injection into the right coronary artery (RCA).
Furthermore, contrast staining was detected close to the
RCA ostium (below, left panel). Transoesophageal echocar-
diography (TOE) showed a focal dissection of the ascending
aorta (below, middle panel). The patient was immediately
referred for computed tomographic (CT) coronary angio-
graphy. The CT examination was performed using a 16 row
multislice CT (Somatom Sensation 16, Siemens, Forchheim,
Germany). Iodinated contrast (Xenetix 300, Guerbert GmbH,
Sulzbach, Germany), 100 ml, was continuously injected into
an antecubital vein. The CT scan showed an intramural
contrast depot and a focal dissection of the ascending aorta
compressing the ostium of the right coronary artery (below,
right panel). A coronary bypass operation was performed
immediately. Two weeks later a follow up CT examination
was performed which showed a patent venous bypass graft to
the proximal RCA.
T Schlosser
H Ku¨hl
T Bartel
J Barkhausen
thomas.schlosser@uni-essen.de
Left: Catheterisation image shows contrast staining around the RCA ostium (arrows). Middle: TOE shows a focal dissection (LD) of the ascending aorta
(Ao) (rPA, right pulmonary artery). Right: Axial CT image demonstrating the dissection flap (thick arrow) of the aorta coursing to the RCA ostium and
the proximal RCA. Intramural contrast depot at the RCA ostium (thin arrow).
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